Avenue Therapeutics regains Nasdaq compliance; bid price and equity requirements satisfied; delisting matter closed

AVENUE THERAPEUTICS, INC.

On Oct 18, 2022, Nasdaq confirmed Avenue Therapeutics met the $1.00 bid price and $2.5M stockholders' equity requirements for continued listing.
The delisting matter is closed; the company previously faced potential delisting for non-compliance with both requirements.
A Nasdaq Hearings Panel granted a stay through Oct 2022 to demonstrate compliance; company successfully met the conditions.
The company is now in full compliance with all applicable Nasdaq Capital Market listing criteria.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.